Zobrazeno 1 - 10
of 316
pro vyhledávání: '"Wei-Peng Yong"'
Autor:
Malia Alexandra Foo, Mingliang You, Shing Leng Chan, Gautam Sethi, Glenn K. Bonney, Wei-Peng Yong, Edward Kai-Hua Chow, Eliza Li Shan Fong, Lingzhi Wang, Boon-Cher Goh
Publikováno v:
Biomarker Research, Vol 10, Iss 1, Pp 1-18 (2022)
Abstract Multiple three-dimensional (3D) tumour organoid models assisted by multi-omics and Artificial Intelligence (AI) have contributed greatly to preclinical drug development and precision medicine. The intrinsic ability to maintain genetic and ph
Externí odkaz:
https://doaj.org/article/f0a8fa04d01c460ea1d92472ba0a469d
Autor:
Lawrence Soon-U Lee, Kok-Yong Seng, Ling-Zhi Wang, Wei-Peng Yong, Kim-Hor Hee, Thomas I Soh, Andrea Wong, Pei F Cheong, Richie Soong, Nur S Sapari, Ross Soo, Lu Fan, Soo-Chin Lee, Boon C Goh
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0147681 (2016)
BACKGROUND:Irinotecan toxicity correlates with UGT1A1 activity. We explored whether phenotyping UGT1A1 using a probe approach works better than current genotyping methods. METHODS:Twenty-four Asian cancer patients received irinotecan as part of the F
Externí odkaz:
https://doaj.org/article/6295a6cdf52940d7a4543df1021b5144
Autor:
Robert John Walsh, Rebecca Ong, Seng Wee Cheo, Peter Q.J. Low, Aishwarya Jayagopal, Matilda Lee, Natalie Ngoi, Samuel G. Ow, Andrea L.A. Wong, Siew Eng Lim, Yi Wan Lim, Valerie Heong, Raghav Sundar, Ross A. Soo, Cheng Ean Chee, Wei Peng Yong, Boon Cher Goh, Soo Chin Lee, David S.P. Tan, Joline S.J. Lim
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionMolecular profiling of metastatic breast cancer (MBC) through the widespread use of next-generation sequencing (NGS) has highlighted actionable mutations and driven trials of targeted therapy matched to tumour molecular profiles, with imp
Externí odkaz:
https://doaj.org/article/98dbdbab3f7349b688320adc069900de
Autor:
Ley-Fang Kua, Soo Ross, Soo-Chin Lee, Kousaku Mimura, Koji Kono, Boon-Cher Goh, Wei-Peng Yong
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e42873 (2012)
Uridine diphosphoglucuronosyltransferases (UGTs) 1A6 is the only UGT1A isoform expressed in lung tissue. It is responsible for the detoxification of carcinogens such as benezo[a]pyrene from cigarette smoke. The purpose of this study was to evaluate t
Externí odkaz:
https://doaj.org/article/488d5d3f845141b186dee5e232902196
Autor:
Foong Ying Wong, Natalia Liem, Chen Xie, Fui Leng Yan, Wing Cheong Wong, Lingzhi Wang, Wei-Peng Yong
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e50786 (2012)
Although gemcitabine is highly active in several cancer types, intrinsic and acquired drug resistance remains a major challenge. Overexpression of Bcl-2 has been associated with gemcitabine resistance. The aim of this study is to determine whether go
Externí odkaz:
https://doaj.org/article/f5c5027d887e4efabdbe7242f902ef83
Autor:
Benjamin Koh, Darren Jun Hao Tan, Wen Hui Lim, Jeffrey S L Wong, Cheng Han Ng, Kai En Chan, Meng Wang, Wei Peng Yong, Yock Young Dan, Louis Z Wang, Nigel Tan, Mark Muthiah, Alfred Kow, Nicholas L. Syn, Daniel Q. Huang, Thomas Yau
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTThe use of immune checkpoint inhibitors (ICIs) targeting PD-L1/PD-1 and CTLA-4 has transformed the oncology practice of hepatocellular carcinoma. However, only 25–30% of the patients with advanced HCC treated with atezolizumab-bevacizumab o
Externí odkaz:
https://doaj.org/article/98077533239642c291b0017f7ac49635
Autor:
Jiahui Yu, Mengnan Li, Boxu Ren, Le Cheng, Xiaoxiao Wang, Zhaowu Ma, Wei Peng Yong, Xiaoguang Chen, Lingzhi Wang, Boon Cher Goh
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing approximately 85% of cases. The diagnosis is often made in the middle and late stages, necessitating systemic treatment as the primary therapeutic option. Despite sorafe
Externí odkaz:
https://doaj.org/article/a2a537e8e9a64b0db06bc7454b93b071
Autor:
Jia Li Low, Yiqing Huang, Kenneth Sooi, Zhi Yao Chan, Wei Peng Yong, Soo Chin Lee, Boon Cher Goh
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The rising cost of oncological drugs poses a global challenge to patients, insurers, and policy makers, with the leading drugs worldwide by revenue from immune checkpoint inhibitors (ICIs). Despite its cost, ICI is marked as a paradigm shift, offerin
Externí odkaz:
https://doaj.org/article/0dd5ed50793047ff8ca7f044e506b976
Autor:
Thomas Yau, David Tai, Stephen Lam Chan, Yi-Hsiang Huang, Su Pin Choo, Chiun Hsu, Tan To Cheung, Shi-Ming Lin, Wei Peng Yong, Joycelyn Lee, Thomas Leung, Tracy Shum, Cynthia S. Y. Yeung, Anna Yin-Ping Tai, Ada Lai Yau Law, Ann-Lii Cheng, Li-Tzong Chen
Publikováno v:
Liver Cancer (2022)
Background: Asia has a high burden of hepatocellular carcinoma (HCC) due to the high rates of chronic hepatitis B infection, and accounts for 70% of HCC cases globally. In the past 20 years, the systemic treatment landscape of advanced HCC has evolve
Externí odkaz:
https://doaj.org/article/40f6cf6d91f4490ba3706de915130645
Autor:
Walsh, Robert John, Ong, Rebecca, Seng Wee Cheo, Low, Peter Q. J., Jayagopal, Aishwarya, Lee, Matilda, Ngoi, Natalie, Ow, Samuel G., Wong, Andrea L. A., Siew Eng Lim, Yi Wan Lim, Heong, Valerie, Sundar, Raghav, Soo, Ross A., Cheng Ean Chee, Wei Peng Yong, Goh, Boon Cher, Soo Chin Lee, Tan, David S. P., Lim, Joline S. J.
Publikováno v:
Frontiers in Oncology; 2024, p1-11, 11p